InMed receives Nasdaq notice for failing equity listing rule
InMed Pharmaceuticals said Nasdaq notified it failed Listing Rule 5550(b)(1) after equity of $1,075,007 vs. $2.5 million requirement. Trading continues on Nasdaq Capital Market under INM; the company has 45 days to submit compliance.